<code id='F80ED32DEF'></code><style id='F80ED32DEF'></style>
    • <acronym id='F80ED32DEF'></acronym>
      <center id='F80ED32DEF'><center id='F80ED32DEF'><tfoot id='F80ED32DEF'></tfoot></center><abbr id='F80ED32DEF'><dir id='F80ED32DEF'><tfoot id='F80ED32DEF'></tfoot><noframes id='F80ED32DEF'>

    • <optgroup id='F80ED32DEF'><strike id='F80ED32DEF'><sup id='F80ED32DEF'></sup></strike><code id='F80ED32DEF'></code></optgroup>
        1. <b id='F80ED32DEF'><label id='F80ED32DEF'><select id='F80ED32DEF'><dt id='F80ED32DEF'><span id='F80ED32DEF'></span></dt></select></label></b><u id='F80ED32DEF'></u>
          <i id='F80ED32DEF'><strike id='F80ED32DEF'><tt id='F80ED32DEF'><pre id='F80ED32DEF'></pre></tt></strike></i>

          knowledge

          knowledge

          author:hotspot    Page View:652
          John-Arne-Røttingen, a white man with short hair, smiles at the camera wearing blue suits — biotech coverage from STAT
          John-Arne Røttingen is the head of the Wellcome Trust, one of the world’s top private funders of biomedical research. Illustration: STAT; Source: Wellcome Trust

          LONDON — The key groups involved in addressing global health problems often include governments, foundations, and pharmaceutical companies.

          But to John-Arne Røttingen, the new head of the Wellcome Trust, one of the world’s top private funders of biomedical research, there’s another sector that should be getting involved — the tech industry.

          advertisement

          The Alphabets and Amazons of the world have been growing their health-related initiatives, but the industry is rarely mentioned when neglected public health issues are discussed, Røttingen argued.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more
          With fresh data, a dynamic duo powers Eli Lilly to new heights
          With fresh data, a dynamic duo powers Eli Lilly to new heights

          EliLillyCEODavidRicks(left)andChiefScientificOfficerDanielS.SkovronskyMollyFergusonforSTATThepartner

          read more
          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more

          In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

          InsitroCEOandfounderDaphneKollerNeilsonBarnard/GettyImagesforTheNewYorkTimesSANFRANCISCO—Ittookonlya